close
randox logo

  • home Home

  • linked_services Solutions keyboard_arrow_down

    • biotech Core Disciplines keyboard_arrow_down

      • View All
      • Quality Control
      • EQA
      • Chemistry
      • Immunoassay
      • Molecular
      • Point of Care
      • Toxicology
      • Food Diagnostics
      • BioSciences
      • BioReagents
      • Veterinary

    • neurology Disease Areas keyboard_arrow_down

      • View All
      • Acute Kidney Injury
      • Alzheimer's Disease
      • Chronic Kidney Disease
      • Chronic Lung Infection
      • Colorectal Cancer
      • Familial Hypercholesterolemia
      • Gastrointestinal
      • Hyperinflammation
      • Immunodeficiency
      • Neurovascular Dysfunction
      • Pancreatic Cancer
      • Urinary Tract Infection
      • Female Bladder Cancer Array
      • Acute Respiratory Distress Syndrome (ARDS)

    • store Online Store

  • experiment Services keyboard_arrow_down

  • support Support & Resources keyboard_arrow_down

  • apartment Company keyboard_arrow_down

    • Our Story
    • Our Vision
    • Partners & Sponsorships
    • Charity Partners
    • Collaborators
    • Careers

  • mail Contact

randox logo
  • Solutions
    keyboard_arrow_down
  • Services
    keyboard_arrow_down
  • Support & Resources
    keyboard_arrow_down
  • Company
    keyboard_arrow_down
  • Contact
Randox Health search menu
Randox Health search

Get in touch to discover more

To find out more about Single Analyte Assays, enquire now.

Make an Enquiry mail
download Download brochure

Randox also provides a range of single-analyte assays for the critical care environment, eliminating the need for lengthy batching periods and reducing wastage, a common issue with larger throughput analysers that require placement in hospital labs and highly specialised training.

DKK-1 Biochip

Quantitative measurement of DKK-1 provides clinicians with insight into bone health, various cancers and pancreatic health. DKK-1 is centrally involved in the regulation of bone remodelling, and its dysregulation is associated with bone pathologies. DKK-1 has emerged as a biomarker of cancer progression and prognosis as well as a potential therapeutic target in various types of malignancies.

DKK-1 is also found to be increased in Pancreatic ductal adenocarcinoma (PDAC) patients. DKK-1 can be a promising biomarker specific to PDAC, which has the potential to increase PDAC survival rates through improving early-stage detection and monitoring progression compared to current biomarker gold standards.

humidity_low Sample Type:
Serum

update Time to Result:
Under 40 minutes

labs Biomarker:
Dickkopf-1 (DKK1)

IL-6 Biochip

IL-6 serves as an early marker of inflammation due to illness or injury, with quantitative measurement of IL-6 providing clinicians with greater insight into a patient’s immune system and its response to both pathogens and treatments.

Belonging to the cytokine family, IL-6 triggers both pro-inflammatory and anti-inflammatory reactions. IL-6 provides general health and inflammation profiling, and has a wide range of applications such as cancers, neuroinflammation, sepsis, ARDS, lymphoma, and rheumatoid arthritis.

humidity_low Sample Type:
Plasma

update Time to Result:
35 Minutes

labs Biomarker:
Interleukin 6 (IL-6)

IL-18 Biochip

IL-18 is a pro-inflammatory cytokine that plays a significant role in the immune system, and its measurement as a biomarker is increasingly used in clinical settings to assess and monitor various inflammatory and immune-mediated conditions.

IL-18 is a key biomarker for inflammatory diseases, disease monitoring and is being explored as an immune booster in CART-cell therapy and other cancer treatments.

humidity_low Sample Type:
Serum

update Time to Result:
35 Minutes

labs Biomarker:
Interleukin 18 (IL-18)

CXCL9 Biochip

CXCL9 (C-X-C motif chemokine ligand 9), also known as monokine induced by gamma interferon (MIG), is a small cytokine that plays a key role in immune system signalling. It is part of the CXC chemokine family and is primarily induced by interferon-gamma (IFN-γ).

CXCL9 has emerged as a valuable biomarker and potential therapeutic target in several clinical contexts including autoimmune disease Lupus Nephritis, Acute Cellular Rejection (ACR) in organ transplant and Inflammatory Bowel Disease Ulcerative Colitis

humidity_low Sample Type:
Serum

update Time to Result:
36 Minutes

labs Biomarker:
CXCL9

RAGE Biochip

Quantitative measurement of Receptor for Advanced Glycation End product (RAGE) provides clinicians with insight into inflammation and cellular signalling.

RAGE is expressed in various cell types, including immune cells, endothelial cells, and neurons. AGE is formed during ageing and is accelerated in pathophysiological states such as diabetes, Alzheimer’s disease, kidney failure, and immune/inflammatory diseases

humidity_low Sample Type:
Serum

update Time to Result:
35 Minutes

labs Biomarker:
Receptor for Advanced Glycation End product (RAGE)

Midkine Biochip

Quantitative measurement of Midkine provides clinicians with insight into a wide range of illnesses such as cancers, autoimmune diseases, heart failure and kidney dysfunction. A soluble secreted protein, Midkine is highly elevated in various illnesses and could serve as a valuable disease biomarker. In many types of cancer, it has been shown to be overexpressed, especially during tumour progression into more advanced stages.

humidity_low Sample Type:
Urine

update Time to Result:
60 Minutes

labs Biomarker:
Midkine

Benefits of the Evidence MultiSTAT

ward Improved Triage

Using biomarker data would improve triage, reduce or defer referral, fast track patients identified as 'high risk', and reduce healthcare burden.

savings Save Hospital Resources

With results from a single sample patients can avoid taking unnecessary and invasive tests

data_array Better Patient Care

Biochip results and refined data-based analysis accelerates medical decisions.

The Evidence MultiSTAT

The Evidence MultiSTAT is an easy to use, small footprint analyser facilitating on-site simultaneous detection of multiple biomarkers.

Using chemiluminescence as a measurement principle, the Evidence MultiSTAT consistently delivers accurate results.

With minimal sample preparation required, this versatile benchtop analyser can achieve accurate, quantitative results in minutes.

MultiSTAT brochure  download

MultiSTAT Cartridge

The Evidence MultiSTAT cartridge contains the reagents required for the chemiluminescent reaction to take place incorporated into its wells.

The process from sample entry to results can be completed in 2 simple steps, with minimal risk of human error.

No other components are required.